Meta AnalysisID 3161
辛伐他汀和洛伐他汀的使用与胶质瘤风险：一项Meta分析
CRD42023384826
Do simvastatin and lovastatin use associated with a low incidence risk of glioma?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 3161
- Evidence Id
- 11719
- Core Evidence Id
- 11719
- Source Meta Analysis Id
- 3110
- Herb2 Meta Analysis Id
- HBMA003110
- Crd Id
- CRD42023384826
- Title
- Simvastatin and Lovastatin Use and the risk of glioma: A Meta-Analysis
- Review Question
- Do simvastatin and lovastatin use associated with a low incidence risk of glioma?
- Study Type Included
- * Inclusion criteria: 1- Patients have gliomas. 2- Search phrases ‘statin’ OR 'simvastatin’ OR ‘lovastatin’ OR ‘hydroxymethylglutaryl CoAreductase inhibitors’ OR ‘HMG-CoA reductase inhibitors) AND (‘glioma') OR ('glioblastoma). 3- Cohort and/or case-control studies investigating the association between simvastatin and lovastatin use and the risk of occurrence of gliomas. * Exclusion criteria: 1- Duplicates research papers. 2- Meta-analyses, reviews, and case reports.
- Condition Being Studied
- Despite different treatment modalities, such as the maximum safe surgical resection, radiation therapy, and chemotherapy with temozolomide, patients with glioblastoma, which is one of the most invasive brain cancers, have an estimated survival of 12 to 18 months after diagnosis. The mevalonate pathway, in particular HMGCR, is fundamentally involved in the growth of GBM, and it was found to be upregulated in a clinical GBM sample. Statins, HMGCR inhibitors, may promote apoptosis by inhibiting extracellular signal-regulated kinase1/2, activating protein kinase B, and downregulating the antiapoptotic protein Bcl-2 in GBM. In preclinical GBM research, statins were shown to block Ras/Rho-prenylation, which prevents the invasion, migration, and differentiation of GBM cells. Only a few clinical trials have proven a link between statins and GBM survival, despite preclinical findings supporting their anticancer participation in GBM. Thus, it is helpful to investigate the effect of statin therapy, including doses and duration, on the risk of glioma incidence according to the outputs of research papers.
- Participant
- * Inclusion criteria: 1- Patients have gliomas. 2- Search phrases ‘statin’ OR 'simvastatin’ OR ‘lovastatin’ OR ‘hydroxymethylglutaryl CoAreductase inhibitors’ OR ‘HMG-CoA reductase inhibitors) AND (‘glioma') OR ('glioblastoma). 3- Cohort and/or case-control studies investigating the association between simvastatin and lovastatin use and the risk of occurrence of gliomas. * Exclusion criteria: 1- Duplicates research papers. 2- Meta-analyses, reviews, and case reports.
- Animal
- Human Disease Modelled
- Intervention
- * Inclusion criteria: 1- Patients have gliomas. 2- Search phrases ‘statin’ OR 'simvastatin’ OR ‘lovastatin’ OR ‘hydroxymethylglutaryl CoAreductase inhibitors’ OR ‘HMG-CoA reductase inhibitors) AND (‘glioma') OR ('glioblastoma). 3- Cohort and/or case-control studies investigating the association between simvastatin and lovastatin use and the risk of occurrence of gliomas. * Exclusion criteria: 1- Duplicates research papers. 2- Meta-analyses, reviews, and case reports.
- Comparator Control
- * Inclusion criteria: 1- Patients have gliomas. 2- Search phrases ‘statin’ OR 'simvastatin’ OR ‘lovastatin’ OR ‘hydroxymethylglutaryl CoAreductase inhibitors’ OR ‘HMG-CoA reductase inhibitors) AND (‘glioma') OR ('glioblastoma). 3- Cohort and/or case-control studies investigating the association between simvastatin and lovastatin use and the risk of occurrence of gliomas. * Exclusion criteria: 1- Duplicates research papers. 2- Meta-analyses, reviews, and case reports.
- Main Outcome
- The results of the current investigation will be concluded if lovastatin and simvastatin use can be protective against the occurrence or bad prognosis of gliomas.
- Outcome Measure
- Additional Outcome
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Anticholesteremic Agents; Glioma; Humans; Incidence; Lovastatin; Simvastatin
- Contact
- Amjad Zuhier Salem Alrosan [email protected] [email protected]
- Organisational Affiliation
- Hashemite University
- Funding Source
- Nothing
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Jordan
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-12-21
- Registration Date
- 2023-01-01
- Anticipated Start Date
- 2022-11-15
- Anticipated Completion Date
- 2023-02-28
- Title Cn
- 辛伐他汀和洛伐他汀的使用与胶质瘤风险：一项Meta分析
- Title En
- Simvastatin and Lovastatin Use and the risk of glioma: A Meta-Analysis
- Bilingual Status
- complete